Q4
Q4 Inc. (“Q4” or “the company”), the IR Ops Platform, today announced it is a winner in the 2024 International Business Awards®. Honored for its “effectiveness in supporting client needs,” the company’s Web Content Services (WCS) team earned a bronze Stevie® Award for “Customer Service Team of the Year” — a category that spanned across industries — underscoring Q4’s commitment to delivering outstanding customer experiences.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240819909828/en/
IBA Bronze Stevie Winner Badge (Graphic: Business Wire)
This is the second year in a row Q4 has been honored in the International Business Awards.
Considered “the Olympics for the workplace,” the International Business Awards (IBAs) are the world’s premier business awards program. All individuals and organizations worldwide – public and private, for-profit and non-profit, large and small — are eligible to submit nominations. The 2024 IBAs received entries from organizations in 62 nations and territories, with more than 3,600 nominations submitted.
Here’s what the judges had to say about Q4’s WCS team:
- “Their achievements reflect exceptional efficiency, accuracy, and client satisfaction.”
- “The team’s ability to handle client requests efficiently, maintain high accuracy, and achieve record CSAT scores highlights their effectiveness in supporting client needs.”
- “Q4’s core company values shine through in the way this team operates.”
- Q4’s WCS team shows “exceptional performance in customer service through impressive metrics, continuous improvement, and a commitment to customer satisfaction.”
- “The WCS team at Q4 has demonstrated outstanding performance.”
“IROs and their teams have a lot on their plates, and we want to alleviate that burden through our AI-driven IR Ops Platform,” said Darrell Heaps, Founder and CEO of Q4. “This recognition from the International Business Awards shows how our amazing Web Content Services team does just that. It also highlights the high-impact results our customers achieve — using Q4 to build investor relationships and make strategic decisions. As we continue to chart a bold, new path for investor relations, we’re committed to innovation that helps IR teams realize remarkable outcomes and frees up their time to focus on what matters: strategy, relationships, and driving premium valuations for their companies.”
Q4: A single, powerful platform for investor relations
Public companies today strive to maintain up-to-date, secure and compliant investor relations websites — so they can demonstrate what they do, attract investors, and motivate them to take action. Q4’s technology makes it easy for some of the world’s biggest brands — McDonald’s, Walmart, Visa, Netflix and many more — to create and manage IR websites that drive results, accelerate website updates (publishing changes within minutes, and 16 times faster than with other tools), streamline earnings management, and tap into real-time analytics on investor behavior. With decades of website design and IR experience, Q4’s award-winning WCS team provides further assistance with website development and change requests, as well as Q4 Platform support.
Websites are just one component of Q4’s holistic IR Ops Platform, an unprecedented and unified system for attracting investors, managing relationships and staying abreast of the market’s pulse. Rather than grapple with disparate and disconnected tools, IR leaders and their companies can access everything they need from a single place: using Q4 for IR websites, virtual events, an IR CRM, surveillance, engagement analytics and more, including secure AI for IR.
Q4’s win in the International Business Awards comes on the heels of other recent milestones and momentum for the company. Q4 has powered more than 18 million investor interactions and hosts 4,400 events annually — with 530,000+ investors connecting to events via the Q4 Platform each month. Named “Best Tech-Driven Capital Markets Platform” by Global Brands Magazine, Q4 serves more than 2,600 global clients, including half of the S&P 500.
About Q4 Inc.
Q4 Inc. is the first IR Ops Platform with the world’s largest set of proprietary investor data, purpose-built to remove obstacles between public companies and their investors. Q4 gives investor relations leaders and their teams the tools to attract, manage, and understand investors — all in one place. The AI-enabled Q4 IR Ops Platform boasts applications for website and event management, engagement analytics, and earnings lifecycle management, including AI Earnings Co-Pilot to generate draft scripts based on historical data, and AI earnings call summaries to understand peer sentiment. The Platform also includes a streamlined investor CRM and shareholder intelligence with enhanced metrics to elevate investor targeting strategies. Q4 delivers the data, insights, and workflows that give IR teams the power to focus on what really matters: strategy, relationships, and driving premium valuations for their companies.
The company is a trusted partner to more than 2,600 public companies globally, including many of the most respected brands in the world, and maintains an award winning culture where team members grow and thrive.
Q4 is headquartered in Toronto, with offices in London and Copenhagen. Learn more at www.q4inc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240819909828/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom